Rapid and accurate diagnosis of influenza is important for patient management and infection control. We determined the performance of the cobas ® Influenza A/B assay, a rapid automated nucleic acid assay performed on the cobas ® Liat System for qualitative detection of influenza A and influenza B from nasopharyngeal (NP) swab specimens. Retrospective frozen and prospectively collected NP swabs from patients with signs and symptoms of influenza collected in universal transport medium (UTM) were tested at multiple sites including CLIA-waived sites using the cobas® Influenza A/B assay. Results were compared to the Prodesse ProFlu+ assay and to viral culture. Compared to the Prodesse ProFlu+ Assay, sensitivities of the cobas ® Influenza A/B assay for influenza A and B were 97.7 and 98.6%, respectively; specificity was 99.2 and 99.4%. Compared to viral culture, the cobas ® Influenza A/B assay showed sensitivities of 97.5 and 96.9% for influenza virus A and B, respectively; specificities were 97.9% for both viruses. Polymerase chain reaction (PCR)/sequencing showed that the majority of viral culture negative but cobas ® Influenza A/B positive results were true positive results, indicating that the cobas ® Influenza A/B assay has higher sensitivity compared to viral culture.
Introduction
Infl uenza is a contagious respiratory illness caused by infl uenza viruses A and B in humans. Worldwide, three to fi ve million individuals develop severe infl uenza each year and 250,000 to 500,000 die of infl uenza-related causes [1] . Even in developed countries, such as the United States, infl uenza is responsible for more than 200,000 hospitalizations annually and 3000 to 49,000 deaths [2] . While hospitalization costs are important contributors, lost productivity from missed work days and lost lives comprise the bulk of the economic burden of infl uenza [3] . Moreover, as illustrated by the 2009 H1N1 pandemic that affected hundreds of countries, infl uenza has the potential to rapidly spread globally.
Early identifi cation of infl uenza is important for optimal patient management and infection control. However, case defi nitions of infl uenza-like illness including cough, sore throat, rhinorrhea, and nasal congestion only have modest sensitivity and specifi city [4, 5] . For this reason, physicians rely on the use of laboratory tests to diagnose infl uenza [6] and initiate prompt administration of antiviral therapy, mainly oseltamivir [7] . Additional benefi ts of rapid identifi cation are infection control, public health notifi cation and tracking, and prevention of unnecessary use of antibiotics, hospital procedures, and laboratory tests [8, 9] .
Current diagnostic techniques for the detection and identifi cation of infl uenza virus include rapid infl uenza detection tests (RIDTs), viral culture, and nucleic acid amplifi cation tests (NAAT). Commercially available RIDTs are widely used in clinical practice as point of care tests because they are simple to use and provide results within 15 to 30 min [10] [11] [12] . However, their sensitivities vary widely depending on the manufacturer and can be as low as 10%, with specifi cities ranging from 90 to 100% [10, 13] . Viral culture has increased sensitivity over both RIDTs and DFAs but requires skilled technologists and specialized laboratory settings and has a long turnaround time (2 to 14 days) [14] . NAAT are highly sensitive and are replacing culture as the gold standard, but these tests are generally more expensive, require highly skilled molecular technologists, and have turnaround times of up to 24 h from receipt to results [15] [16] [17] [18] [19] [20] . In clinical practice, specimens with negative RIDTs are usually tested subsequently by more sensitive culture or molecular assays. Based on the poor performance of RIDTs, the Food and Drug Administration (FDA) has recently proposed tightening standards for rapid infl uenza tests in order to avoid impeding of diagnosis and treatment of infl uenza patients (http://www. gpo.gov/fdsys/pkg/FR-2014-05-22/html/2014-11635. htm?source=govdelivery&utm_medium=email&utm_ source=govdelivery). To mitigate the risks of false-negative and (equally detrimental) false-positive results from RIDTs, special measures that identify the minimum acceptable performance criteria, identify appropriate comparators for establishing performance of new assays, and mandate annual analytical reactivity testing of contemporary infl uenza strains should be implemented.
Polymerase chain reaction (PCR)-based molecular assays have shown excellent clinical utility for the detection and identifi cation of infl uenza viruses; numerous FDAcleared commercial devices are now available [17, 21, 22] . More recently, an isothermal amplifi cation-based test with fast turnaround time and simplicity has been described [23, 24] .
In the present study, we investigated the performance of the cobas ® Infl uenza A/B assay (Roche Molecular Systems, Pleasanton, CA) for the detection and differentiation of infl uenza A and infl uenza B viruses in nasopharyngeal swab (NPS) specimens. We observed very high sensitivity and specifi city for the detection of both infl uenza A and B viruses compared to viral culture and PCR/sequencing. High accuracy combined with the ease of use and rapid time to result should prove useful for the management of patients with suspected infl uenza.
Materials and methods

Clinical study design
Clinical trials to demonstrate the clinical performance of the cobas ® Infl uenza A/B assay on the cobas ® Liat System were performed using two sets of patient samples. First, nasopharyngeal swabs (retrospective samples) obtained in 2013-2014 from TriCore Reference Laboratories (Albuquerque, NM) and Lahey Clinic (Burlington, MA) were archived at −80 °C upon receipt. Samples were distributed to three CLIA waived sites (Advanced Pediatrics, Vienna, VT; Meridian Clinical Research, Bellevue, NE; Med Center Medical Clinic, Fair Oaks, CA) for testing, and results were compared to those obtained in the Prodesse ProFlu+ Assay (Hologic, MA, USA) [22, 25] .
During the 2008/9, 2013/14, and 2014/15 fl u seasons, 12 CLIA-waived sites in the US prospectively collected nasopharyngeal swabs. Of these, nine sites were primary care offi ces, and three sites were hospital emergency departments. Thirty-three operators participated in the study, including ten nurses, 14 medical assistants, one administrative assistant, one nurse aide, two personnel with Emergency Medical Technician training, and fi ve other personnel with no formal medical training. Patients were enrolled based on the following inclusion criteria: presence (self-reported) of two or more fl u-like clinical signs and symptoms (fever; headache; extreme tiredness; dry cough; sore throat; runny or stuffy nose; muscle aches; and gastrointestinal symptoms, such as nausea, vomiting, and diarrhea) within the past 48 h. Subjects taking antiviral medication at the time of the visit or within 7 days of the visit or who had received a nasal fl u vaccine within the last 6 weeks were excluded. Nasopharyngeal swabs collected in universal transport medium (UTM) from each patient were tested using the cobas ® Infl uenza A/B assay at clinical sites, and the Prodesse ProFlu+ Assay ( Hologic, MA, USA) [22, 25] , and viral culture at reference laboratories. To prevent sampling bias, samples from the same vial used for testing with the cobas ® Infl uenza A/B assay were used for viral culture and the ProFlu+ assay, if available. Bidirectional sequencing was used to investigate discordant results.
cobas ® Liat System
The cobas ® Liat System is a new point-of-care instrument with sample-to-answer capabilities in which all sample processing steps as well as detection are carried out using a single-use, disposable Liat Tube (Fig. 1A-C) . Each test cartridge handles one sample and has a unique barcode identifi er that is scanned into the cobas ® Liat System to code the sample ID. An NPS sample is loaded directly into a Liat assay tube using a transfer pipette. After the tube is capped, the cobas ® Liat System scans the tube barcode, and the tube is inserted into the analyzer. Specimen sampling and handling is controlled using multiple sample processing modules contained within the cobas ® Liat System. The sample processing modules are composed of two assemblies, a moving side assembly comprised of multiple sample processing plungers and clamps, and a fi xed side assembly. When performing an assay, a Liat tube is inserted into the tube slot of a cobas ® Liat System. The plungers and clamps selectively compress the Liat tube segments against the fi xed side assembly to release reagents from the segments, move the sample from one segment to another, and control reaction conditions. Test cartridges are single use and part of a closed system. An internal control used in conjunction with procedural checks monitors instrument functionality, performance, fl uidics, and result determination based on a predefi ned decision algorithm. The cobas ® Liat System is 510(k) cleared by the US Food and Drug Administration (FDA).
cobas ® Influenza A/B assay
The cobas ® Infl uenza A/B assay uses an established nucleic acid test chemistry and assay protocol for the detection of viral RNA. The sample preparation methodology is based on lysis by a chaotropic agent followed by magnetic particle based nucleic acid purifi cation. First, the NPS sample in UTM is diluted and mixed with an internal process control (IPC). Second, nucleic acids are isolated from lysates through binding to silica magnetic beads in the presence of the chaotropic salt followed by removal of possible inhibitors. Target amplifi cation and detection use TaqMan-probe based real-time polymerase chain reaction (RT-PCR). The infl uenza A primer and probe set detects matrix RNA from type A infl uenza virus, and infl uenza B primer and probe sets detect nonstructural protein RNA from infl uenza B viruses. An IPC primer and probe set is also included to amplify the target region of the internal control. Dual-labeled fl uorogenic hydrolysis (TaqMan) probes anneal to specifi c target sequences and are degraded causing reporter dyes to separate from the quenchers, thereby generating fl uorescent signals and cycle threshold (Ct) values for the specifi c analytes.
The internal process control (IPC) comprises an encapsulated RNA that is prepacked in each Liat tube. When conducting an assay, it is fi rst mixed with sample and then processed through all the test steps to monitor both the sample preparation and the RT-PCR reaction performance. The IPC RNA is detected in a separate channel by IPC specifi c primers and probe.
Positive control is provided in the cobas ® Infl uenza A/B assay Quality Control Kit. The positive control comprises of inactivated Infl uenza A and B virus. Negative control is provided in the cobas ® Infl uenza A/B assay Quality Control Kit. The negative control comprises UTM.
The limit of detection (LOD) of the assay was determined as the lowest log virus concentration that was detected ≥95% of the time (i.e., log concentration at which at least 19 out of 20 replicates tested positive). The LOD for three strains of Infl uenza A were 10 −2 to 10 −1 TCID50/ ml, while those for the two strains of Infl uenza B were 10 −3 to 10 −1 TCID50/ml. The reactivity of the cobas ® Infl uenza A/B assay has been confi rmed for a large number of infl uenza A and infl uenza B strains from multiple geographical regions including contemporary strains (cobas ® Infl uenza A/B assay package insert). The assay demonstrated no cross reactivity with a large number of non-infl uenza respiratory pathogens and other microorganisms which may be found in NPS specimens, nor did the presence of such other microorganisms interfere with the detection of infl uenza. The cobas ® Infl uenza A/B assay does not show inhibition when nasopharyngeal samples contain relevant concentrations of potentially interfering substances including antiviral (zanamivir, oseltamivir), antibacterial (tobramycin, muporicin) drugs, nasal sprays (ozymetazoline, fl utocasone), throat lozenges, anaesthetics, analgesics, or nasal gels.
The workfl ow of the cobas ® Infl uenza A/B assay is shown in Fig. 1 . The entire workfl ow takes ~1 min of human resource time, and the assay generates results in only 20 min.
The assay is 510(k)-cleared by the FDA, and the FDA has recently granted CLIA (Clinical Laboratory Improvement Amendments) waiver for the cobas ® Infl uenza A/B test for use on the cobas ® Liat System.
Performance using fresh vs. frozen samples
The performance of the cobas ® Infl uenza A/B assay was tested comparing results obtained using fresh and frozen specimens. One infl uenza A strain (A/Brisbane/10/07) and one infl uenza B strain (B/Malaysia/2506/04) were individually spiked into NPS matrix at different viral loads, including levels near LOD and levels refl ecting the clinical range. For each strain, 60 samples were tested immediately while another 60 samples were frozen at −80 °C for 7 days, thawed, and then tested.
Reference testing
Reference testing using viral culture was performed concurrent with the prospective sample collection in 2008 Reference testing using the Prodesse ProFlu+ Assay was performed by Cleveland Clinic (Cleveland, OH). PCR and bidirectional sequencing was used as the reference method for retrospective samples, as well as to investigate discordances in prospective sample results. The protocol utilized was adapted from Ghedin et al. [26, 27] Inf A discordant samples were tested with both the Inf A and 2009 H1N1 primer sets. For infl uenza B, discordant samples were tested using the Inf B primer sets. Twenty microliters (20 μl) of the purifi ed RNA was used as template in a 30 μl RT-PCR reaction using the Qiagen One-
Step RT-PCR kit. The fi rst RT-PCR was performed using a thermal protocol comprising: 1) a reverse transcription step of 50 °C for 30 min; 2) an initial denaturation step of 94 °C for 15 min; 3) 50 cycles of denaturing at 94 °C for 30 s, annealing at 50 °C for 30 s, and extension at 72 °C for 60 s; and 4) a fi nal extension step of 72 °C for 10 min. First RT-PCR products were diluted 1:100 in molecular grade water and used as template in the subsequent second PCR. Two microliters (2 μl) of the diluted fi rst RT-PCR product was combined with 28 μl PCR Mastermix containing the corresponding second (nested) PCR primers. The second PCR was performed using a thermal protocol comprising: 1) an initial denaturation step of 94 °C for 2 min; 2) 30 cycles of denaturing at 94 °C for 15 s, annealing at 55 °C for 30 s, and extension at 72 °C for 30 s. After amplifi cation, fi ve microliters (5 μl) of second PCR product was loaded onto a 2% agarose gel and electrophoresed at 100 volts using 1× TAE buffer. After electrophoresis, gels were visualized under ultraviolet (UV) light and appropriately sized gel bands were excised. DNA from each gel fragment was purifi ed with the Qiagen MinElute Gel Extraction Kit and eluted in 20 μl of 10 mM Tris buffer, pH 8.5. Two microliters (2 μl) of the gel extract was combined with 0.5 μl of 100 μM sequencing primer and 17.5 μl of ddH2O for a total of 20 μl primer-target mix. The mix was then sent to the Massachusetts General Hospital DNA Core Facility for sequencing. After obtaining the sequencing data, NCBI BLAST search was used against the nucleotide collection (nr/nt) database. Acceptance criteria for sequence analysis were a) sequence contains a minimum of 200 overlapping contiguous bases, b) bases have a Quality Value of 20 or higher as measured by PHRED (probability of an error of 1% or lower), and c) sequence matches the reference or consensus sequence with an expected value (E value) <10
−30 for the specifi c target. If only one direction of the bidirectional sequencing data met the acceptance criteria, the sequencing procedure was repeated by performing PCR using diluted amplicon from the previous PCR as template. The new PCR product was then sent for bidirectional sequencing. If the retest still did not yield results where both directions met the acceptance criteria, the sample was called "indeterminate".
Positive and negative controls were tested with each batch of samples. Positive controls comprised of NP swab matrix spiked with A/NY/01/2009 H1N1, A/Brisbane/59/07, and B/Malaysia/2506/04, respectively, to give a fi nal concentration of 1.0 TCID50/ml. Negative control comprised blank NP swab matrix.
Statistical analysis
Sensitivity and specifi city of the cobas ® Infl uenza A/B assay were determined and compared to reference results including the Prodesse ProFlu+ Assay and viral culture; results obtained by discordant analysis were not used to recalculate assay performance. Ninety-fi ve percent confidence intervals are stated.
Ethical considerations
The study was approved by the Institutional Review Boards with waiver of Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization. All patients completed the Informed Consent Form. When under the age of 18, parents provided guardian consent; patients aged 6-17 provided the Minor Assent form. Exclusion criteria were the absence of fl u-like symptoms and current antiviral medication. 
Results
Performance of the cobas
Discussion
The ideal diagnostic technique for the management of patients with suspected infl uenza A and B must combine high accuracy, speed, and ease of use. While viral cell culture and molecular diagnostic techniques are considered the "gold standard" for detection of infl uenza A and B due to their high accuracy, they lack speed and ease of use [6, 10] . Rapid antigen tests are therefore commonly used in outpatient clinics, physicians' offi ces, and in some hospitals despite the fact that they have insuffi cient sensitivity [10] . In the present multicenter study, we evaluated the performance of the cobas ® Infl uenza A/B assay rapid point of care test that has recently been cleared and CLIA-waived by the FDA. Based on the results observed, the cobas ® Infl uenza A/B assay addresses the requirements of accuracy, speed, and ease of use needed to provide management decisions for patients with suspected infection with infl uenza A and B.
First, using a collection of 300 retrospective nasopharyngeal swabs from U.S. sites, the cobas ® Infl uenza A/B assay demonstrated sensitivities of 98.8 and 100% for the detection of infl uenza A and B, respectively, compared to the ProdessaFlu+ assay. Discordant testing using PCR/ sequencing supported the results obtained in the cobas ® Infl uenza A/B test. The excellent sensitivity was accompanied by excellent specifi cities of 100% for both infl uenza A and B.
Second, we compared the cobas ® Infl uenza A/B assay with the Prodesse ProFlu+ test using a large number of prospectively collected samples. Accuracy of the cobas ® Infl uenza A/B assay was excellent and mirrored the results obtained in the retrospective sample set. Overall, the sensitivity and specifi city of the cobas ® Infl uenza A/B assay in retrospective and prospective samples were 97.7 and 98.6% for the detection of infl uenza A, respectively, and 98.6 and 99.4% for the detection of infl uenza B. PCR and bidirectional sequencing used to further investigate discordant results showed that the cobas ® Infl uenza A/B assay detected infl uenza virus in certain specimens that gave negative results in the ProdessaFlu+ assay.
To confi rm these fi ndings, we then compared the cobas ® Infl uenza A/B assay to viral culture considered the gold standard by some. The observed sensitivity was 97.5% for infl uenza A and 96.9% for infl uenza B. Similarly, this high sensitivity was achieved while maintaining a very high specifi city of 97.9% for both infl uenza A and B. PCR and bidirectional sequencing used to investigate the discordant results confi rmed the results obtained in the cobas ® Infl uenza A/B assay in the majority of cases. Recently, several PCR-based assays have been FDAcleared for the detection of infl uenza A and B. The Luminex Xtag and Biofi re FilmArray tests cover infl uenza A and B virus in addition to a number of other respiratory viruses [22, 28, 29] while the Prodesse ProFlu+ test detects infl uenza A and B and RSV [22] and the Cepheid Xpert Flu assay detects infl uenza A and B [9, 30] . Sensitivities of these assays for the detection of infl uenza virus A and B range between 90 and 100%. While showing slightly lower or similar accuracy compared to the cobas ® Infl uenza A/B assay, these PCR-based tests do not offer the neces- data not shown). Specifi cities for the detection of infl uenza A and B were high for both methods. These results are consistent with recent literature reporting the low sensitivity of rapid antigen tests for the detection of infl uenza virus [31] [32] [33] . While these tests are widely used based on their speed and ease of use, they are characterized by a high rate of false negative results that require confi rmatory testing using culture or molecular tests. Furthermore, the low accuracy may result in a signifi cant numbers of misdiagnoses affecting quality and costs of patient management.
The Alere i Infl uenza A&B assay is isothermal-amplifi cation-based and detects infl uenza virus A and B and has been compared to other diagnostic tests [23, 24, [34] [35] [36] . The reported sensitivity for infl uenza A compared with viral culture and the Prodesse ProFlu+, FilmArray RP, and Xpert Flu A/B ranged from 70 to 99%, and the specifi city ranged from 62 to 100%; for infl uenza B, the sensitivity ranged from 91.8-100% and the specifi city ranged from 53 to 100% reported by others [24, 34, 35] . The sensitivity was markedly lower in another study, particularly for the detection of infl uenza B [36] .
Conversely, the cobas ® Liat RT-PCR technology demonstrated high sensitivity and equivalent performance compared other RT-PCR-based tests. Compared to the Simplexa Flu A/B & RSV PCR assay, the cobas ® Infl uenza A/B assay achieved sensitivities of 99.2 and 100% for infl uenza A and B, respectively; the specifi city was 100% for each target resulting in an overall agreement of 99.5% [37] . While both the Alere test and cobas ® Infl uenza A/B assay are considered point-of-care solutions and demonstrate comparable time to result, the user-friendliness and low human resource time of the cobas ® Infl uenza A/B assay are markedly less than the same features using the Alere i Infl uenza A&B test procedure. Two sequences of manual steps are required for the Alere assay with a three-minute wait time between each sequence. The sample is not added until after the three-minute wait. In contrast, the cobas ® Infl uenza A/B assay (Fig. 1 ) runs automatically to a result after sample insertion in the setup. Future studies will have to directly compare the accuracy, time to result, human-resource time, and overall clinical value of these molecular point-of-care tests for the detection of infl uenza A and B.
Comparing currently available techniques for the diagnosis of infection with infl uenza virus A and B, the cobas ® Infl uenza A/B assay -to our knowledge -is the fi rst test that combines the high accuracy of molecular techniques or viral culture with the speed and ease of use of rapid antigen tests.
In regard to speed and ease of use, the total time to result was 20 min, and the total hands-on time to start the test was ~1 min. Thus, the time to result is only slightly longer than the one observed using rapid antigen tests but still well within the time frame needed to impact the management of patients with suspected infl uenza in outpatient clinics, emergency room, or on regular and intensive care wards. The ease of use of the cobas ® Liat System is further underlined by the fact that testing of samples in this trial was conducted by personnel having received only minimal training at the initiation of the study. The ease of use and minimal human resource time also lends itself to expand testing to other settings such as pharmacies and practitioner's offi ces. The small footprint of the cobas ® Liat System adds to the value of this technology, i.e., in a true point-of-care setting.
The ease-of-use is further underlined by the fact that the prospective collection of NPS was performed by operators who had limited or no training or hands-on experience in conducting laboratory tests. Operators included nurses, medical assistants, administrative assistants, nurse aides, personnel with Emergency Medical Technician training, or other personnel with no formal medical training. Operators were only provided with labeling and product materi- Liat assay compared to the standard of care (GenMark RVP assay with provider judgment) in the emergency room. Introduction of the cobas ® Liat assay had a significant impact on clinical management as changes in patient management occurred in 86 (57%) of 150 patients studied in the emergency room. Patient management changes included changes to antiviral-antimicrobial stewardship (53%), changes in admission/discharge orders (17%), and changes to procedures/lab orders (19%). Of interest, 61% of patients in whom management was changed had a negative cobas ® Infl uenza A/B result. Previous studies have found that the mean length of stay in the hospital for inpatients with respiratory viral isolates was reduced by almost 50%, and mean variable costs for these patients were reduced by 2/3 after introduction of rapid testing [38] Thus, the introduction of highly accurate and PCR-based rapid tests is likely to have signifi cant clinical benefi ts ranging from decreases in turnaround time, mortality, length of stay, and overall costs; at the same time, these benefi ts will also result in improved antibiotic stewardship.
PCR testing offers signifi cant improvements in accuracy over rapid antigen testing and/or clinical judgment [39] . The trade-off is that molecular assays are more expensive than rapid antigen tests. All new rapid molecular systems should be compared to both rapid antigen testing and PCR to validate their accuracy, ease of use, and degree of benefi t offered. Rapid antigen tests have demonstrated striking differences in accuracy and, the same may prove to be true for POC molecular tests based on PCR and other molecular techniques. Additional studies and health economic analysis are needed to assess the performance benefi ts, cost, and reimbursement of new molecular testing.
Our study has limitations. First, performance characteristics for infl uenza A were prospectively established at infl uenza seasons when particular infl uenza strains including A/H1 and A/H3 were the predominant infl uenza A viruses in circulation. However, 180 other infl uenza A and B strains obtained from the CDC were successfully identifi ed by the cobas ® Infl uenza A/B assay and analytical studies also included a large number of infl uenza strains of temporal and geographic diversity (data not shown). Furthermore, data generated to demonstrate changes in patient management were generated from a limited cohort of patients with suspected infl uenza. Therefore, future studies will have to demonstrate the overall outcome benefi ts of the cobas ® Infl uenza A/B assay for the management of these patients.
In conclusion, the cobas ® Infl uenza A/B assay demonstrated excellent sensitivity and specifi city compared to viral culture and a comparator PCR-based molecular test; performance compared to standard rapid antigen tests was markedly superior. Results were generated within 20 min, and the assay could be performed by personnel untrained in laboratory procedures. Results of the present study strongly support the use of the cobas ® Infl uenza A/B assay for the detection of infl uenza A and B in nasopharyngeal specimens obtained from patients with suspected infl uenza.
